Highlights and Quick Summary
- EBITDA Margin for the quarter ending December 31, 2022 was 97.23% (a -457.2% decrease compared to previous quarter)
- Year-over-year quarterly EBITDA Margin decreased by -329.37%
- Annual EBITDA Margin for 2022 was -232.65% (a -49.11% decrease from previous year)
- Annual EBITDA Margin for 2021 was -457.14% (a 197.42% increase from previous year)
- Annual EBITDA Margin for 2020 was -153.7% (a 161.08% increase from previous year)
- Twelve month EBITDA Margin ending December 31, 2022 was -232.65% (a 36.71% increase compared to previous quarter)
- Twelve month trailing EBITDA Margin decreased by -24.87% year-over-year
Trailing EBITDA Margin for the last four month:
| 31 Dec '22 | 30 Sep '22 | 30 Jun '22 | 31 Mar '22 |
|---|---|---|---|
| -232.65% | -170.18% | -328.08% | -309.67% |
Visit stockrow.com/PGEN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA Margin of Precigen, Inc.
Most recent EBITDA Marginof PGEN including historical data for past 10 years.Interactive Chart of EBITDA Margin of Precigen, Inc.
Precigen, Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | 97.23% | -27.22% | -701.51% | -42.39% | -232.65% |
| 2021 | 113.63% | -441.79% | -507.89% | -46.33% | -457.14% |
| 2020 | 54.64% | -69.3% | 16.12% | -31.5% | -153.7% |
| 2019 | 297.31% | -181.41% | -88.06% | -185.29% | -58.87% |
| 2018 | -557.82% | -151.13% | -48.71% | -108.84% | -200.26% |
| 2017 | 46.59% | -84.43% | -66.75% | -41.23% | -30.5% |
| 2016 | -26.0% | -46.92% | 12.48% | -28.16% | -21.28% |
| 2015 | -74.69% | 51.5% | 15.73% | -587.62% | -112.53% |
| 2014 | -172.57% | 120.15% | 153.06% | -478.42% | -66.34% |
| 2013 | -283.58% | -619.15% | -300.66% | 443.6% | -254.82% |
| 2012 | -358.32% | -779.46% | – | – | -442.01% |
Business Profile of Precigen, Inc.
Sector: Healthcare
Industry: Biotechnology